C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay

Correspondence: Graciela Russomando, grusso@rieder.net.py; Jonathan Hoffmann, jonathan.hoffmann@fondation-merieux.org

Saved in:
Bibliographic Details
Main Author: Russomando Alvarez, Graciela Mabel (author)
Other Authors: Sanabria Martínez, Diana Leticia (author), Díaz Acosta, Chyntia Carolina (author), Arenas, Rossana (author), Rojas Vera, Leticia Elizabeth (author), Franco, Laura Ximena (author), Arenas Chaparro, María Rossana (author), Delogu, Giovanni (author), Bousso Ndiaye, Mame Diarra (author), Bayaa, Rim (author), Rakotosamimanana, Niaina (author), Goletti, Delia (author), Hoffmann, Jonathan (author)
Format: article
Language:English
Published: 2024
Subjects:
Online Access:https://doi.org/10.3389/fimmu.2024.1308015
http://hdl.handle.net/20.500.14066/4587
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1870612064051920896
author Russomando Alvarez, Graciela Mabel
author2 Sanabria Martínez, Diana Leticia
Díaz Acosta, Chyntia Carolina
Arenas, Rossana
Rojas Vera, Leticia Elizabeth
Franco, Laura Ximena
Arenas Chaparro, María Rossana
Delogu, Giovanni
Bousso Ndiaye, Mame Diarra
Bayaa, Rim
Rakotosamimanana, Niaina
Goletti, Delia
Hoffmann, Jonathan
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author_browse Arenas Chaparro, María Rossana
Arenas, Rossana
Bayaa, Rim
Bousso Ndiaye, Mame Diarra
Delogu, Giovanni
Díaz Acosta, Chyntia Carolina
Franco, Laura Ximena
Goletti, Delia
Hoffmann, Jonathan
Rakotosamimanana, Niaina
Rojas Vera, Leticia Elizabeth
Russomando Alvarez, Graciela Mabel
Sanabria Martínez, Diana Leticia
author_facet Russomando Alvarez, Graciela Mabel
Sanabria Martínez, Diana Leticia
Díaz Acosta, Chyntia Carolina
Arenas, Rossana
Rojas Vera, Leticia Elizabeth
Franco, Laura Ximena
Arenas Chaparro, María Rossana
Delogu, Giovanni
Bousso Ndiaye, Mame Diarra
Bayaa, Rim
Rakotosamimanana, Niaina
Goletti, Delia
Hoffmann, Jonathan
author_role author
bitstream.checksum.fl_str_mv 5fa4fd9ae8d64ec8c11dca2c78a50870
733ff759cb84997119b89b3501ee5132
0175ea4a2d4caec4bbcc37e300941108
858b22fda432bd774e469302988c1974
7a1dac41a22db1deadee45fb92a02de9
07143bf5ec347771d51a8aa05181f6c1
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
MD5
bitstream.url.fl_str_mv http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4587/1/C1q%20and%20HBHA-specific%20IL-13%20levels%20as%20surrogate%20plasma%20biomarkers%20for%20monitoring%20tuberculosis%20treatment%20efficacy.pdf
http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4587/5/Material%20suplementario.zip
http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4587/2/license_rdf
http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4587/3/license.txt
http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4587/4/C1q%20and%20HBHA-specific%20IL-13%20levels%20as%20surrogate%20plasma%20biomarkers%20for%20monitoring%20tuberculosis%20treatment%20efficacy.pdf.txt
http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4587/6/C1q%20and%20HBHA-specific%20IL-13%20levels%20as%20surrogate%20plasma%20biomarkers%20for%20monitoring%20tuberculosis%20treatment%20efficacy.jpg
dc.contributor.other.es.fl_str_mv Universidad Nacional de Asunción. Instituto de Investigaciones en Ciencias de la Salud
dc.creator.none.fl_str_mv Russomando Alvarez, Graciela Mabel
Sanabria Martínez, Diana Leticia
Díaz Acosta, Chyntia Carolina
Arenas, Rossana
Rojas Vera, Leticia Elizabeth
Franco, Laura Ximena
Arenas Chaparro, María Rossana
Delogu, Giovanni
Bousso Ndiaye, Mame Diarra
Bayaa, Rim
Rakotosamimanana, Niaina
Goletti, Delia
Hoffmann, Jonathan
dc.date.accessioned.none.fl_str_mv 2025-06-10T21:28:45Z
dc.date.available.none.fl_str_mv 2025-06-10T21:28:45Z
dc.date.issued.none.fl_str_mv 2024-03-13
dc.format.extent.es.fl_str_mv 10 páginas
dc.identifier.citation.en.fl_str_mv Russomando, G., Sanabria, D., Díaz Acosta, C. C., Rojas, L., Franco L., Arenas, R., Delogu, G., Bousso Ndiaye M. D., Bayaa, R., Rakotosamimanana, N., Goletti, D., & Hoffmann, J. (2024). C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay. Frontiers in Immunology, 15, Article 1308015. https://doi.org/10.3389/fimmu.2024.1308015
dc.identifier.doi.es.fl_str_mv 10.3389/fimmu.2024.1308015
dc.identifier.essn.es.fl_str_mv 1664-3224
dc.identifier.other.es.fl_str_mv https://doi.org/10.3389/fimmu.2024.1308015
dc.identifier.uri.none.fl_str_mv http://hdl.handle.net/20.500.14066/4587
dc.language.iso.es.fl_str_mv eng
dc.publisher.en.fl_str_mv International Union of Immunological Societies
dc.publisher.es.fl_str_mv Frontiers Media S.A.
dc.relation.projectCONACYT.es.fl_str_mv PINV18-1322
dc.rights.*.fl_str_mv Atribución 4.0 Internacional
dc.rights.accessRights.es.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by/4.0/
dc.subject.classification.es.fl_str_mv 7. Salud
7.3. Prevención, vigilancia y control de enfermedades transmisibles y no transmisibles
dc.subject.ocde.es.fl_str_mv 3. Ciencias Médicas y de la Salud
3.3. Ciencias de la Salud (salud pública, medicina social, higiene, enfermería, epidemiología)
dc.subject.other.es.fl_str_mv Host biomarkers
Immunodiagnostic
Plasma protein signature
Pulmonary tuberculosis
Treatment immunomonitoring
dc.title.es.fl_str_mv C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay
dc.type.es.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
description Correspondence: Graciela Russomando, grusso@rieder.net.py; Jonathan Hoffmann, jonathan.hoffmann@fondation-merieux.org
eu_rights_str_mv openAccess
format article
id CONACYT_02ca2addf2cacdd8c4ceef2987cc2971
identifier_str_mv Russomando, G., Sanabria, D., Díaz Acosta, C. C., Rojas, L., Franco L., Arenas, R., Delogu, G., Bousso Ndiaye M. D., Bayaa, R., Rakotosamimanana, N., Goletti, D., & Hoffmann, J. (2024). C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay. Frontiers in Immunology, 15, Article 1308015. https://doi.org/10.3389/fimmu.2024.1308015
10.3389/fimmu.2024.1308015
1664-3224
language eng
network_acronym_str CONACYT
network_name_str Repositorio Institucional CONACYT
oai_identifier_str oai:repositorio.conacyt.gov.py:20.500.14066/4587
publishDate 2024
publishDateSort 2024
repository.mail.fl_str_mv repositorio.institucional@conacyt.gov.py
repository.name.fl_str_mv Repositorio Institucional CONACYT
repository_id_str
rights_invalid_str_mv Atribución 4.0 Internacional
http://creativecommons.org/licenses/by/4.0/
spelling 10236001043600348600f0c36c71-f913-4d86-ac84-b3f3b9e8eb4a60013594780-4998-444e-b28e-382f94b334436004526001891c568-1671-4cdf-8f41-ca410b5f055f600ce26e7fa-5b3b-487c-bed9-3994f712a5c4600b5d13d0d-d254-4d21-bfcb-703d071623d16006d49eb68-0bf6-45e0-abbc-f9642c4ad0826000739782d-30f2-4a48-99f4-f929e1d7d3fd6008cc05825-580c-4c61-9d55-9b5a2f3b367c6000ccae167-14ab-4316-af77-6295ed2b3ee4600Universidad Nacional de Asunción. Instituto de Investigaciones en Ciencias de la Salud2025-06-10T21:28:45Z2025-06-10T21:28:45Z2024-03-13Russomando, G., Sanabria, D., Díaz Acosta, C. C., Rojas, L., Franco L., Arenas, R., Delogu, G., Bousso Ndiaye M. D., Bayaa, R., Rakotosamimanana, N., Goletti, D., & Hoffmann, J. (2024). C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay. Frontiers in Immunology, 15, Article 1308015. https://doi.org/10.3389/fimmu.2024.1308015https://doi.org/10.3389/fimmu.2024.1308015http://hdl.handle.net/20.500.14066/458710.3389/fimmu.2024.13080151664-3224Correspondence: Graciela Russomando, grusso@rieder.net.py; Jonathan Hoffmann, jonathan.hoffmann@fondation-merieux.orgIntroduction: New diagnostic tools are needed to rapidly assess the efficacy of pulmonary tuberculosis (PTB) treatment. The aim of this study was to evaluate several immune biomarkers in an observational and cross-sectional cohort study conducted in Paraguay. Methods: Thirty-two patients with clinically and microbiologically confirmed PTB were evaluated before starting treatment (T0), after 2 months of treatment (T1) and at the end of treatment (T2). At each timepoint plasma levels of IFN-y, 17 pro- and anti-inflammatory cytokines/chemokines and complement factors C1q, C3 and C4 were assessed in unstimulated and Mtb-specific stimulated whole blood samples using QuantiFERON-TB gold plus and recombinant Mycobacterium smegmatis heparin binding hemagglutinin (rmsHBHA) as stimulation antigen. Complete blood counts and liver enzyme assays were also evaluated and correlated with biomarker levels in plasma. Results: In unstimulated plasma, C1q (P<0.001), C4 (P<0.001), hemoglobin (P<0.001), lymphocyte proportion (P<0.001) and absolute white blood cell count (P=0.01) were significantly higher in PTB patients at baseline than in cured patients. C1q and C4 levels were found to be related to Mycobacterium tuberculosis load in sputum. Finally, a combinatorial analysis identified a plasma host signature comprising the detection of C1q and IL-13 levels in response to rmsHBHA as a tool differentiating PTB patients from cured TB profiles, with an AUC of 0.92 (sensitivity 94% and specificity 79%). Conclusion: This observational study provides new insights on host immune responses throughout anti-TB treatment and emphasizes the role of host C1q and HBHA-specific IL-13 response as surrogate plasma biomarkers for monitoring TB treatment efficacy.Consejo Nacional de Ciencia y TecnologíaPrograma Paraguayo para el Desarrollo de la Ciencia y Tecnología. Proyectos de investigación y desarrollo10 páginasengFrontiers Media S.A.International Union of Immunological SocietiesAtribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccess© 2024 Russomando, Sanabria, Díaz Acosta, Rojas, Franco, Arenas, Delogu, Ndiaye, Bayaa, Rakotosamimanana, Goletti and Hoffmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.7. Salud7.3. Prevención, vigilancia y control de enfermedades transmisibles y no transmisiblesHost biomarkersImmunodiagnosticPlasma protein signaturePulmonary tuberculosisTreatment immunomonitoring3. Ciencias Médicas y de la Salud3.3. Ciencias de la Salud (salud pública, medicina social, higiene, enfermería, epidemiología)C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguayinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionFrontiers in ImmunologyPINV18-132215Russomando Alvarez, Graciela MabelSanabria Martínez, Diana LeticiaDíaz Acosta, Chyntia CarolinaArenas, RossanaRojas Vera, Leticia ElizabethFranco, Laura XimenaArenas Chaparro, María RossanaDelogu, GiovanniBousso Ndiaye, Mame DiarraBayaa, RimRakotosamimanana, NiainaGoletti, DeliaHoffmann, JonathanORIGINALC1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy.pdfC1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy.pdfArtículo científicoapplication/pdf1879869http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4587/1/C1q%20and%20HBHA-specific%20IL-13%20levels%20as%20surrogate%20plasma%20biomarkers%20for%20monitoring%20tuberculosis%20treatment%20efficacy.pdf5fa4fd9ae8d64ec8c11dca2c78a50870MD51Material suplementario.zipMaterial suplementario.zipMaterial suplementarioapplication/octet-stream145629http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4587/5/Material%20suplementario.zip733ff759cb84997119b89b3501ee5132MD55CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8908http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4587/2/license_rdf0175ea4a2d4caec4bbcc37e300941108MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-81698http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4587/3/license.txt858b22fda432bd774e469302988c1974MD53TEXTC1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy.pdf.txtC1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy.pdf.txtExtracted texttext/plain45325http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4587/4/C1q%20and%20HBHA-specific%20IL-13%20levels%20as%20surrogate%20plasma%20biomarkers%20for%20monitoring%20tuberculosis%20treatment%20efficacy.pdf.txt7a1dac41a22db1deadee45fb92a02de9MD54THUMBNAILC1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy.jpgC1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy.jpgVista de primera página de artículo científicoimage/jpeg392350http://repositorio.conacyt.gov.py/bitstream/20.500.14066/4587/6/C1q%20and%20HBHA-specific%20IL-13%20levels%20as%20surrogate%20plasma%20biomarkers%20for%20monitoring%20tuberculosis%20treatment%20efficacy.jpg07143bf5ec347771d51a8aa05181f6c1MD5620.500.14066/4587oai:repositorio.conacyt.gov.py:20.500.14066/45872026-02-12 19:30:41.743Repositorio Institucional CONACYTrepositorio.institucional@conacyt.gov.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
spellingShingle C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay
Russomando Alvarez, Graciela Mabel
7. Salud
7.3. Prevención, vigilancia y control de enfermedades transmisibles y no transmisibles
Host biomarkers
Immunodiagnostic
Plasma protein signature
Pulmonary tuberculosis
Treatment immunomonitoring
3. Ciencias Médicas y de la Salud
3.3. Ciencias de la Salud (salud pública, medicina social, higiene, enfermería, epidemiología)
status_str publishedVersion
title C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay
title_full C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay
title_fullStr C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay
title_full_unstemmed C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay
title_short C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay
title_sort C1q and HBHA-specific IL-13 levels as surrogate plasma biomarkers for monitoring tuberculosis treatment efficacy: a cross-sectional cohort study in Paraguay
topic 7. Salud
7.3. Prevención, vigilancia y control de enfermedades transmisibles y no transmisibles
Host biomarkers
Immunodiagnostic
Plasma protein signature
Pulmonary tuberculosis
Treatment immunomonitoring
3. Ciencias Médicas y de la Salud
3.3. Ciencias de la Salud (salud pública, medicina social, higiene, enfermería, epidemiología)
url https://doi.org/10.3389/fimmu.2024.1308015
http://hdl.handle.net/20.500.14066/4587